top
Please input keywords
Pipeline
Develop antibody drugs to meet patients' needs
Biocytogen is dedicated to the development of novel antibody drugs to meet the unmet medical needs, with a particular focus on oncology, autoimmune, inflammatory, metabolic, and other diseases. The company’s pipeline includes more than 10 assets including monoclonal antibodies, bispecific antibodies, bispecific ADCs, etc. By advancing its R&D capabilities and striving for clinical excellence, Biocytogen aims to deliver transformative therapies to patients in need.
Clinical pipeline
Therapeutic Area
Product Candidate
Target(s)
Molecular Format
Mono/Combo Therapy
Indication(s)
Development
Preclinical
IND
Phase l
Phase ll
Phase III
Rights
Partner
Oncology
YH003
CD40
mAb
PD-1+ chemo
Pancreatic ductal adenocarcinoma (1L&2L)
Global MRCT
Global
More
PD-1+ chemo
Mucosal melanoma
China
Global
More
PD-1+ YH001
Solid tumors
Global MRCT
Global
More
YH001
CTLA-4
mAb
PD-L1+chemo
Sarcoma
America
Outside North America

North America
More
YH002
OX40
mAb
YH001
Solid tumors
Global MRCT
Global
More
YH003+YH001
Intratumoral injection
Pre-IND
More
YH004
4-1BB
mAb
Mono
Solid tumor + Hematological malignancy
Australia and China
Global
More
YH008
PD-1 x CD40
BsAb
Mono
Solid tumors
China
ex-Greater China

Greater China
More
Clinical pipeline
Oncology
YH003
More
Target(s):
CD40
Molecular Format:
mAb
Mono/Combo Therapy:
PD-1+ chemo
Indication(s):
Pancreatic ductal adenocarcinoma (1L&2L)
Preclinical
IND
Phase l
Phase ll
Phase III
Rights:
Global
Partner:
YH003
More
Target(s):
CD40
Molecular Format:
mAb
Mono/Combo Therapy:
PD-1+ chemo
Indication(s):
Mucosal melanoma
Preclinical
IND
Phase l
Phase ll
Phase III
Rights:
Global
Partner:
YH003
More
Target(s):
CD40
Molecular Format:
mAb
Mono/Combo Therapy:
PD-1+ YH001
Indication(s):
Solid tumors
Preclinical
IND
Phase l
Phase ll
Phase III
Rights:
Global
Partner:
YH001
More
Target(s):
CTLA-4
Molecular Format:
mAb
Mono/Combo Therapy:
PD-L1+chemo
Indication(s):
Sarcoma
Preclinical
IND
Phase l
Phase ll
Phase III
Rights:
Outside North America
Partner:
North America
YH002
More
Target(s):
OX40
Molecular Format:
mAb
Mono/Combo Therapy:
YH001
Indication(s):
Solid tumors
Preclinical
IND
Phase l
Phase ll
Phase III
Rights:
Global
Partner:
YH002
More
Target(s):
OX40
Molecular Format:
mAb
Mono/Combo Therapy:
YH003+YH001
Indication(s):
Intratumoral injection
Preclinical
IND
Phase l
Phase ll
Phase III
Rights:
Partner:
YH004
More
Target(s):
4-1BB
Molecular Format:
mAb
Mono/Combo Therapy:
Mono
Indication(s):
Solid tumor + Hematological malignancy
Preclinical
IND
Phase l
Phase ll
Phase III
Rights:
Global
Partner:
YH008
More
Target(s):
PD-1 x CD40
Molecular Format:
BsAb
Mono/Combo Therapy:
Mono
Indication(s):
Solid tumors
Preclinical
IND
Phase l
Phase ll
Phase III
Rights:
ex-Greater China
Partner:
Greater China
Preclinical pipeline
Therapeutic Area
Product Candidate
Target(s)
Molecular Format
Indication(s)
Development
Discovery
Hits
selection
Leads
selection
Candidate
selection
Preclinical
IND
Rights
Partner
Oncology
YH012
HER2 x TROP2
BsADC
Solid tumors
Global
Radiance
More
YH013
EGFR x MET
BsADC
Solid tumors
YH016
Undisclosed
Undisclosed
Oncology
Global
Inflammation and Autoimmunity
YH015
CD40 inhibitor
mAb
Autoimmunity
Global
More
YH017
Undisclosed
Undisclosed
Autoimmunity
Global
Oncology
BCG003
TNFR2
mAb
Oncology
Ex. Greater China
Dragonboatbio
More
BCG008
SIGLEC15
mAb
Oncology
Ex. Greater China
Undisclosed
More
BCG011
TROP2 x EGFR
BsADC
Oncology
BCG012
HER3 x MUC1
BsADC
Oncology
BCG001
B7-H3
mAb
Oncology
Global
Mabworks
More
BCG005
CCR8
mAb
Oncology
Global
LiberoThera
More
BCG007
AMHR2
mAb
Oncology
Global
Undisclosed
More
BCG010
NKG2A
mAb
Oncology
Ex. Greater China
Undisclosed
BCG006
WT1
TCRm
Oncology
Ex. Greater China
Undisclosed
BCG013
5T4 x MET
BsADC
Oncology
Infectious Diseases
BCG004
Rabies virus
mAb
Infectious diseases
Ex. Greater China
Undisclosed
Rare Diseases
BCG009
Undisclosed
mAb
Rare diseases
Ex. Greater China
Undisclosed
Preclinical pipeline
Oncology
YH012
More
Target(s):
HER2 x TROP2
Molecular Format:
BsADC
Indication(s):
Solid tumors
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner:
Radiance
Rights:
Global
YH013
Target(s):
EGFR x MET
Molecular Format:
BsADC
Indication(s):
Solid tumors
Hits selection
Leads selection
Candidate selection
Preclinical
IND
YH016
Target(s):
Undisclosed
Molecular Format:
Undisclosed
Indication(s):
Oncology
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Rights:
Global
Inflammation and Autoimmunity
YH015
More
Target(s):
CD40 inhibitor
Molecular Format:
mAb
Indication(s):
Autoimmunity
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Rights:
Global
YH017
Target(s):
Undisclosed
Molecular Format:
Undisclosed
Indication(s):
Autoimmunity
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Rights:
Global
Oncology
BCG003
More
Target(s):
TNFR2
Molecular Format:
mAb
Indication(s):
Oncology
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner:
Dragonboatbio
Rights:
Ex. Greater China
BCG008
More
Target(s):
SIGLEC15
Molecular Format:
mAb
Indication(s):
Oncology
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner:
Undisclosed
Rights:
Ex. Greater China
BCG011
Target(s):
TROP2 x EGFR
Molecular Format:
BsADC
Indication(s):
Oncology
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner:
BCG012
Target(s):
HER3 x MUC1
Molecular Format:
BsADC
Indication(s):
Oncology
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner:
BCG001
More
Target(s):
B7-H3
Molecular Format:
mAb
Indication(s):
Oncology
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner:
Mabworks
Rights:
Global
BCG005
More
Target(s):
CCR8
Molecular Format:
mAb
Indication(s):
Oncology
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner:
LiberoThera
Rights:
Global
BCG007
More
Target(s):
AMHR2
Molecular Format:
mAb
Indication(s):
Oncology
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner:
Undisclosed
Rights:
Global
BCG010
Target(s):
NKG2A
Molecular Format:
mAb
Indication(s):
Oncology
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner:
Undisclosed
Rights:
Ex. Greater China
BCG006
Target(s):
WT1
Molecular Format:
TCRm
Indication(s):
Oncology
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner:
Undisclosed
Rights:
Ex. Greater China
BCG013
Target(s):
5T4 x MET
Molecular Format:
BsADC
Indication(s):
Oncology
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner:
Infectious Diseases
BCG004
Target(s):
Rabies virus
Molecular Format:
mAb
Indication(s):
Infectious diseases
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner:
Undisclosed
Rights:
Ex. Greater China
Rare Diseases
BCG009
Target(s):
Undisclosed
Molecular Format:
mAb
Indication(s):
Rare diseases
Hits selection
Leads selection
Candidate selection
Preclinical
IND
Partner:
Undisclosed
Rights:
Ex. Greater China